Floatz logo

BUSULFANUM

Anemia

Masonic Cancer Center, University of MinnesotaSmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Anemia cohort.

Asset / SponsorPhaseRating
Epoetin Alfa
Mayo Clinic
Phase 4BBB
ERYTHROPOIETIN
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
Epoetin Beta
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 4BBB
Ferric Carboxymaltose [Ferinject]
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 4BBB
Cyclophosphamide
OHSU Knight Cancer Institute
Phase 4BBB

View all 50 →

Same molecule, other indications

BUSULFANUM is also rated in:

myelodysplastic/myeloproliferative neoplasmActive
BBB
Indicative · Phase 2/3
76 / 100
View asset →
graft versus host diseaseActive
BBB
Indicative · Phase 4
74 / 100
View asset →
disease related to hematopoietic stem cell transplantActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →